Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE.
FILSPARI vs OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing diuresis and lowering blood pressure.
200 mg orally once daily, with or without food.
Oral, one tablet once daily. Starting dose: Olmesartan medoxomil 20 mg / hydrochlorothiazide 12.5 mg. Titrate up to maximum 40 mg / 25 mg daily as needed.
None Documented
None Documented
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Olmesartan: terminal half-life ~10–15 hours; no accumulation. Hydrochlorothiazide: terminal half-life ~6–15 hours; prolonged in renal impairment.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Olmesartan: ~60% renal, ~35% fecal. Hydrochlorothiazide: ~70% renal (unchanged), ~30% biliary/fecal.
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB